Why Vertex Pharmaceuticals (VRTX) Stock Hit a One-Year High Today

NEW YORK (TheStreet) -- Vertex Pharmaceuticals  (VRTX) soared to a 52-week high of $98.80 on Tuesday after the company reported extremely positive results from two crucial Phase III trials.

Vertex reported statistically significant lung function improvement in patients with the most common form of cystic fibrosis after a combination therapy of two drugs VX-809, also known as lumacaftor, and Kalydeco. The two studies, called "Traffic" and "Transport," each met their primary endpoints separately.

When considered together together, cystic fibrosis patients treated with the greater of two doses of VX-809 and Kalydeco showed a 3.3% improvement in lung function on an absolute basis compared to placebo.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was up 40.89% to $93.85 at 10:06 a.m.

For more on this story, read TheStreet's Adam Feuerstein's article here.

VRTX Chart

VRTX data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Feed the Beast: Cramer's 'Mad Money' Recap (Thursday 1/4/18)

Feed the Beast: Cramer's 'Mad Money' Recap (Thursday 1/4/18)

Cramer: 2017 Was a Year of Resurrection and Revival

Cramer: 2017 Was a Year of Resurrection and Revival

Dow Jumps After Fed Rate Hike, Posts New Record for Fourth Straight Day

Dow Jumps After Fed Rate Hike, Posts New Record for Fourth Straight Day

Dow, S&P 500 on Track to Extend Winning Streaks to 5 Days Before Fed Meeting

Dow, S&P 500 on Track to Extend Winning Streaks to 5 Days Before Fed Meeting